Clinical Observation Of Conbercept In The Treatment Of Macular Edema Secondary To Retinal Occusion

Purpose:To observe and evaluate the efficacy and safety of intravitreal injection of Conbercept in the treatment of macular edema(ME)secondary to retinal vein occlusion(RVO),and to analyze the possible factors affecting prognosis vision.Methods:Retrospective analysis of 42 patients who were diagnosed with Retinal vein occlusion-macular edema(RVO-ME)in the Department of Ophthalmology,the First Affiliated Hospital of Chongqing Medical University from 2017 to 2018,including 23 patients with central retinal vein occlusion(CRVO),19 patients with branch retinal vein occlusion(BRVO),and all of them were monocular.After obtaining the patient's consent,all patients were treated with intravitreal Conbercept 0.5mg/0.05 ml injection.The injection protocol was performed according to 1+prn.The best corrected visual acuity(BCVA),central macular thickness(CMT),intraocular pressure(IOP)and other adverse reactions were recorded before treatment and 1m,2m,3m,6m after treatment.Statistical analysis was performed using SPSS22.0 software.Results:1.Before treatment and 1m,2m,3m,6m after treatment,the average BCVA(logMAR)of 19 patients with BRVO was0.70±0.23,0.54±0.29,0.48±0.22,0.46±0.25,0.53±0.32,respectively;the average BCVA(logMAR)of 23 patients with CRVO was 1.08±0.55,0.61±0.40,0.57±0.37,0.60±0.35,0.70±0.47,respectively.The differences in BCVA were statistically significant(P<0.01).2.Before treatment and at 1m,2m,3m,6m after treatment,the average CMT(?m)of 19 patients with BRVO was 509.16±111.62,312.37±195.17,302.21±92.52,292.00±100.54,302.42±113.71,respectively;the average CMT(?m)of 23 patients with CRVO was 614.78±160.52,332.00±101.66,320.83±135.91,311.43±68.57,327.74±62.39 respectively.The differences in CMT were statistically significant(P<0.01).3.In patients with CRVO,the initial BCVA in the prognosis BCVA ?0.1 group was worse than the prognosis BCVA > 0.1 group,and the CMT was thicker,the difference was statistically significant(P < 0.05).4.Compared with CRVO,the average BCVA after treatment of patients with BRVO was better,and the difference was statistically significant(P<0.05).5.During the follow-up period of this study,except for subconjunctival hemorrhage after treatment in 2 patients,no other adverse reactions occurred in the remaining patients.Conclusion:1.Intravitreal injection of Conbercept in the treatment ofRVO-ME can effectively reduce macular edema and improve vision acuity,and the treatment is safe and reliable.2.The prognostic visual acuity of CRVO patients was related to the initinal visual acuity and CMT.The initinal visual acuity was better and the CMT was thinner,the prognostic visual acuity was better.3.The prognostic visual acuity of BRVO after Conbercept treatment was better than CRVO.